Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6atac small nuclear 13, pseudogene (RNU6ATAC13P)** is a member of the U6atac small nuclear RNA gene family, but it is classified as a pseudogene, meaning that it does not code for a functional RNA product. The U6atac family comprises small nuclear RNAs that are integral to the minor spliceosome, participating in the splicing of a rare class of introns in pre-mRNA. However, as a pseudogene, RNU6ATAC13P is typically regarded as non-functional and is the product of retrotranspositional or duplication events that rendered it inactive. It does not act as a receptor, enzyme, transporter, or direct therapeutic target, and there is no evidence of a biological or pathological function, nor of drug interactions or disease relevance[7][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 13, pseudogene (RNU6ATAC13P).